Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.

@article{Ninomiya1990ComparativeSO,
  title={Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.},
  author={Y Ninomiya and Nobuo Shimma and Hideo Ishitsuka},
  journal={Antiviral research},
  year={1990},
  volume={13 2},
  pages={
          61-74
        }
}
Studies of various analogs related to the antirhinovirus agent 4'-ethoxy-2'-hydroxy-4,6'-dimethoxychalcone (Chalcone Ro 09-0410) led to the identification of amide analogs that are 4.5 to 10 times more active against human rhinovirus (HRV) in tissue culture as measured by chemotherapeutic indices. Chalcone amides Ro 09-0535, Ro 09-0696 and Ro 09-0881 inhibited viral replication at concentrations as low as less than 2-3 ng/ml and were cytotoxic between 30 to 50 micrograms/ml. These compounds… Expand
Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives.
TLDR
The studies on the mechanism of action of IS-44 demonstrated that it prevents the thermal inactivation of HRV 2 infectivity, probably due to a conformational shift in the viral capsid and a decrease in affinity for the cellular receptor, resulting in an inhibition of attachment of the virions. Expand
In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity
TLDR
Pirodavir is a novel capsid-binding antipicornavirus agent with potent in vitro activity against both group A and group B rhinovirus serotypes, and appears to be serotype specific. Expand
Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
TLDR
The adsorption of four out of the seven serotypes was inhibited by some antiviral compounds, but not by others, indicating that the conformational alterations induced by antiv viral compounds can vary considerably within a given serotype, depending on the chemical nature of the antiviral compound used. Expand
Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
TLDR
The binding affinities and the rates of association and dissociation of members of a chemical class of antiviral compounds at their active sites in human rhinovirus type 14 (HRV-14) were determined and may have implications for the molecular design of capsid-binding antirhinovirus drugs. Expand
SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
TLDR
Inhibition of viral uncoating, as demonstrated with echovirus 9, probably is the predominant mode of action of SDZ 35-682. Expand
A comprehensive review on the antiviral activities of chalcones
TLDR
A summary of the antiviral activities of chalcones and their derivatives on a set of human viral infections and their potential for targeting the most recent COVID-19 disease is provided. Expand
The human rhinovirus: human‐pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery
TLDR
This review will summarize existing structural knowledge about HRV, focus on mechanisms of anti‐HRV agents from synthetic and natural origin, and demonstrate strategies for efficient lead structure discovery. Expand
Cytotoxic and antiviral activities of Colombian medicinal plant extracts of the Euphorbia genus.
Forty-seven plant extracts of 10 species of the genus Euphorbia (Euphorbiaceae) used by Colombian traditional healers for the treatment of ulcers, cancers, tumors, warts, and other diseases, wereExpand
Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment.
TLDR
The history and current status of the research that has focused on inhibitors of the early steps in the virus life cycle: attachment to the cellular receptor and uncoating of the viral RNA currently possess the greatest potential for generating a safe and efficacious treatment for the rhinovirus common cold. Expand
Synthesis and in Vitro Antitumor Activity of a Novel Series of 2-Pyrazoline Derivatives Bearing the 4-Aryloxy-7-chloroquinoline Fragment
TLDR
The 2-pyrazoline derivatives bearing the 4-aryloxy-7-chloroquinoline fragment are considered to be useful leads for the rational design of new antitumor agents. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 13 REFERENCES
Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime
TLDR
Results indicate that Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 exert their activities through the same mode of action, namely, binding to or interaction with some specific site on the viral capsid protein, and that the binding or interaction sites for these three agents are either the same or very close to each other. Expand
Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
TLDR
It is concluded that Ro 09-0415 given orally is unlikely to be of value in the prophylaxis or therapy of human rhinovirus infection. Expand
Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
TLDR
Results suggest that Ro 09-0410 binds to the HRV-2 virion and prevents viral replication in the cell, as revealed by infectivity measurements after extraction of the agent with chloroform. Expand
Antipicornavirus flavone Ro 09-0179
TLDR
It is suggested that Ro 09-0179 interferes with some process of viral replication which occurs between viral uncoating and the initiation of viral RNA synthesis. Expand
A 'new' generation of more potent synthetic antirhinovirus compounds: comparison of their MICs and their synergistic interactions.
TLDR
The synergistic interaction between these new synthetic substances and also with some of the earlier compounds such as DCF and enviroxime is reported and the possible implication of this synergistic activity regarding the future prevention and treatment of common colds caused by rhinoviruses is discussed. Expand
In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug
WIN 51711 (5-[7-[4-(4,5-dihydro-2-oxazolyl)phenoxy]heptyl]-3-methylisoxazole), a new antipicornavirus drug, is a potent inhibitor of human entero- and rhinoviruses at concentrations not inhibitory toExpand
Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds.
TLDR
Binary combinations of these drugs showed synergistic activity of which the combinations of HuIFN-gamma or HuIFn-alpha and enviroxime were of most interest and indicate that such combinations of drugs may be worthy of clinical study. Expand
4′,6-Dichloroflavan (BW683C), a new anti-rhinovirus compound
TLDR
Examining the antiviral activity of flavan derivatives with a view to selecting the compound most suitable for trial in volunteers infected with a common cold virus finds a simple derivative, BW683C, is the most potent antiviral compound yet reported. Expand
RMI 15,731 (1-[5-tetradecyloxy-2-furanyl]-ethanone), a new antirhinovirus compound
TLDR
RMI 15,731 appears to be a promising new antirhinovirus compound for clinical evaluation since it (i) blocks intracellular virus synthesis (without cellular toxicity), and (ii) directly inactivates virions. Expand
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.
TLDR
Two compounds are structurally related, antiviral compounds that inhibit the replication of rhino (common cold) viruses and related picornaviruses and prevent the pH-mediated uncoating of the viral RNA. Expand
...
1
2
...